About Saleem

Saleem Kamili, PhD, is Chief of the Laboratory Branch, Division of Viral Hepatitis at the US Centers for Disease Control and Prevention (CDC). He has been working for 20 years at CDC on various aspects of hepatitis viruses including pathogenesis, vaccine design and delivery and diagnostics. Dr. Kamili received the Young Scientist Award and Himalayan Gold Medal during his graduate studies and was recently awarded the MS Balayan Medal for his contributions to the study of hepatitis E. He co-authored CDC’s updated guidelines on testing for hepatitis C virus infection. He serves as Associate Editor of the Journal of Medical Virology and Journal of Clinical Virology. His laboratory is actively involved in improving viral hepatitis diagnostics globally and is partnering with various international institutions in achieving this goal.

This speaker will be presenting at the following session(s)

  • Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity

    Plenary

    Day: 2 November

    Time: 09:30

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".

    Presentations:

    • Conclusions from the World Hepatitis Summit 2015 and progress made.
      Charles Gore, World Hepatitis Alliance
    • 5 core interventions to reach HBV and HCV elimination.
    • Dr. Yvan Hutin, World Health Organization
    • Access to treatment.
    • Shiba Phurailatpam, APN Plus
    • Diagnostics: present and future.
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Hepatitis C prevention and treatment for vulnerable (or marginalised) populations.
    • Professor Gregory Dore, Kirby Institute, UNSW Sydney and St Vincent’s Hospital, Sydney

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.
  • Testing interventions

    Parallel workshop

    Day: 2 November

    Time: 11:30

    Presentations:

    • WHO testing guidelines.
    • Professor Philippa Easterbrook, World Health Organization
    • Overview of rapid assays for viral hepatitis agents: what test for what setting?
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Are screening campaigns feasible and acceptable: the PROLIFICA experience.
    • The national strategic plan in Georgia.
    • Dr. Amiran Gamkrelidze, National Center for Disease Control and Public Health of Georgia

    Session objectives:

    • Review the scientific, logistical, ethical and political process leading to the implementation of state-of-the-art testing for viral hepatitis.
    • Discuss the feasibility and validity of diagnostic algorithm simplifications.
    • Define what testing strategies should be applied in different settings.
    • Discuss the preliminary results of testing strategies in selected areas.